Baird raised the firm’s price target on Agilon Health (AGL) to $35 from $20 and keeps a Neutral rating on the shares. The firm updated its model following strong Q1 results and big guidance raise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL: